{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": {
    "pdf_name": "CDC_Influenza_vaccines",
    "source_pdf": "data/clinical_files/CDC Influenza vaccines.pdf",
    "total_pages": 2,
    "total_blocks": 23,
    "total_characters": 2237
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "Flublok Quadrivalent (RIV4) (Sanofi Pasteur) 0.5-mL PFS \u226518 yrs 45 \u00b5g/0.5 mL IM",
      "relevance_explanation": "This quote shows that Flublok contains 45 \u00b5g of hemagglutinin (HA) antigen per 0.5 mL dose, which is three times the 15 \u00b5g/0.5 mL dose found in standard-dose flu vaccines, directly supporting the first part of the claim."
    },
    {
      "id": 2,
      "quote": "Standard-dose inactivated influenza vaccines contain 15 \u00b5g of HA per virus strain per 0.5 mL dose.",
      "relevance_explanation": "This quote establishes the HA content of standard-dose flu vaccines, providing a direct comparison to Flublok's higher HA content and supporting the claim of a 3x difference."
    },
    {
      "id": 3,
      "quote": "In clinical studies, Flublok demonstrated higher immunogenicity compared with standard-dose, egg-based inactivated influenza vaccines.",
      "relevance_explanation": "This quote directly links the use of Flublok (with its higher HA content) to greater immunogenicity compared to standard-dose flu vaccines, supporting the second part of the claim."
    }
  ],
  "model_used": "gpt-4.1"
}